Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-05-30
2006-05-30
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C424S136100, C530S387300, C536S023530
Reexamination Certificate
active
07052872
ABSTRACT:
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
REFERENCES:
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 0263046 (1988-04-01), None
patent: 0 419 387 (1990-09-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0 623 675 (1993-11-01), None
patent: WO 96/04313 (1996-02-01), None
patent: WO 99/66951 (1999-12-01), None
De Jonge et al, Molecular Immunology, 32, 1405-1412, 1995.
Van Spriel et al, Immunology Today, 21, 391-396, 2000.
Hawkins, et al.; “Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexagte in an Affinity System,”;Cancer Research; vol. 53; May 1993; pp. 2368-2373.
Goodwin et al.; “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Bifunctional Haptens,”;J. Nucl, Med.; vol. 29; 1998; pp. 226-234.
Stickney et al.; “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,”;Cancer Research; vol. 51; Dec. 15, 1991; pp. 6650-6655.
Gautherot et al.; “Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten,”;Cancer Supplement; vol. 80; 1997; pp. 2618-2623.
Barbet et al.; “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium,”;The Journal of Nuclear Medicine; vol. 39, No. 7; Jul. 1998.
Kranenborg et al.; “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,”;Cancer Research Supplement; vol. 55; Dec. 1, 1995; pp. 5864s-5867s.
Schuhmacher et al.; “Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography,”;Cancer Research; vol. 55; Jan. 1, 1995; pp. 115-123.
Sharkey et al.; “Development of a Streptavidin—Anti- Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method For Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model,”;Bioconjugate Chemical; vol. 8, No. 4; 1997.
K. Bosslet et al., “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy”, Macmillan Press Ltd., British Journal of Cancer, (1991) 63/5, 681-686, XP-002120437.
Marion H.G.C. Kranenborg et al., “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma” Cancer Research, (Dec. 1995), 55 (23 Supp.), 5864S-5867S, XP-002120435.
Corine Manetti et al., “Intracellular Uptake and Catabolism of Anti-IgM Antibodies and Bi-Specific Antibody-Targeted Hapten by B-Lymphoma Cells”, International Journal of Cancer, (1995), 63(2), 250-256, XP-002120770.
Manuel Bardies et al., “Bispecific Antibody and Iodine-131-Labeled Bivalent Hapten Dosimetry in Patients with Medullary Thyroid or Small-Cell Lung Cancer”, Journal of Nuclear Medicine, vol. 37, (Nov. 1996), 1853-1859, XP-002116384.
J. Barbet et al., “Radioimmunotherapy of LS174T Colon Carcinoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with An Anti-CEA x Anti-Indium-DTPA Bispecific Antibody”, Tumor Biology, (Sep. 1997), vol. 18, No. Supp. 2, 31, XP-002120771.
Emmanuel Gautherot, “Therapy for Colon Carcinoma Xenografts with Bispecific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten”, American Cancer Society, vol. 80, No. Supp. 12, (Dec. 1997), 2618-2623, XP-002110873.
Marion H.G.C. Kranenborg et al., “Two-Step Radio Immunotargeting of Renal-Cell Carcinoma Xenografts in Nude Mice with Anti-Renal-Cell-Carcinoma x Anti-DTPA Bispecific Monoclonal Antibodies”, International Journal of Cancer, (Jan. 1998), 75 (1), 74-80, XP-002120436.
Francoise Kraeber-Bodere et al., “Phase I/II Trial of Two-Step Radioimmunotherapy in Medullary Thyroid Cancer (MTC) Using Bispecific Anti-CEA/Anti-DTPA-In Antibody and Iodine-131-Labeled Bivalent Hapten”, Journal of Nuclear Medicine, (May 1998), vol. 39, No. 5 Supp., 246, XP-002120769.
Makoto Hosono et al., “Biodistribution and Dosimetric Study in Medullary Thyroid Cancer Xenograft Using Bispecific Antibody and Iodine-125-Labeled Bivalent Hapten”, Journal of Nuclear Medicine, (Sep. 1998), 39 (9),1608-1613, XP-002120434.
Emmanuel Gautherot et al., “Delivery of Therapeutic Doses of Radioiodine Using Bispecific Antibody-Targeted Bivalent Haptens”, Journal of Nuclear Medicine, (Nov. 1998), 39 (11),1937-1943, XP-002120432.
Francoise Kraeber-Bodere et al., “Bispecific Antibody and Bivalent Hapten Radioimmunotherapy in CEA-Producing Medullary Thyroid Cancer Xenograft”, Journal of Nuclear Medicine, (Jan. 1990), 40 (1), 198-204, XP-002120433.
H. Karacay et al., “Studies on a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct for radioimmunotherapy of CEA-positive tumors”, American Assoc. for Cancer Research Annual Meeting (Mar. 1999), vol. 40, 644, XP-002120429.
H. Karacay et al., “Pretargeting Studies with Humanized Anti-CEA x Murine Anti-[In-DTPA] Bispecific Antibody Construct and Tc-99M/ Re-188 Labeled Peptide”, Journal of Nuclear Medicine, (May 1999), vol. 40, No. 5 Supp., 225, XP-002120430.
B.T. McGuinness et al., “Phage diabody repertoires for selection of large numbers of bispecific anitbody fragments,”Nature Biotechnology, 14:1149-1154 (1996).
M. Alt et al., “Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region,”FEBS LETT, 454: 90-94 (1999).
T.B. Olafsen et al., “IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,”Immunotechnology, 4(2):141-153 (1998).
S.M. Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,”J. Mol. Biol., 293(1):41-56 (1999).
Griffiths Gary L.
Hansen Hans J.
Leung Shui-on
McBride William J.
Qu Zhengxing
Faegre & Benson LLP
Immunomedics Inc.
Saunders David
LandOfFree
Bi-specific antibodies for pre-targeting diagnosis and therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bi-specific antibodies for pre-targeting diagnosis and therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bi-specific antibodies for pre-targeting diagnosis and therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3599848